# Raajit K. Rampal

Source: https://onco.cc/people/raajit-rampal/  
OnCo record `raajit-rampal` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New York haematologist who led MANIFEST-2, the trial testing whether adding the BET inhibitor pelabresib to ruxolitinib helps people with myelofibrosis more than ruxolitinib alone.

## Summary

Raajit Rampal directs the myeloproliferative neoplasms programme at Memorial Sloan Kettering Cancer Center. He was the global lead investigator and first author of the primary report of MANIFEST-2, the phase 3 trial of pelabresib plus ruxolitinib against placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis, which met its spleen-volume primary endpoint. His research covers the genetics of progression from chronic myeloproliferative neoplasms to acute leukaemia.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: mpn; trialist
- Role: Haematologist, Memorial Sloan Kettering Cancer Center
- Specialisms: Myelofibrosis; Myeloproliferative neoplasms; Combination therapy trials

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [MANIFEST-2](https://onco.cc/trials/manifest-2/)

---
JSON: https://onco.cc/api/v1/entities/raajit-rampal.json